ERBB3 and triple-negative breast carcinoma: Interestingly, increased HER family ligands were shown to mediate resistance to anti-AKT inhibitors in triple-negative breast cancer cells, which was abrogated by targeting both EGFR and HER3 with a dual receptor ligand-blocking antibody [47].